Eric Hodies – A Study in Attitude and Self-Advocacy
The Diagnosis
IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
The Diagnosis
OBJECTIVE:
To assess the response to antithymocyte globulin based immunosuppressive therapy (IST) in pediatric patients with idiopathic aplastic anemia.
METHODS:
Thirty patients (19 boys and 11 girls) with aplastic anemia received antithymocyte globulin and cyclosporine. Twenty-two patients had severe and 8 had very severe aplastic anemia.
RESULTS:
Antibodies have been the cornerstone of treatment of acquired
The HLA class II DRB1 antigen DR15 (common alleles *1501, *1502) is an important marker in the pathobiology of severe
PURPOSE:
Acquired aplastic anemia is an organ-specific auto-immune disease characterized by pancytopenia and hypoplastic bone marrow. Immunosuppression with anti-thymocyte globulin (ATG) and cyclosporine A (CsA) is an effective and safe therapy for patients without undergoing hematopoietic stem cell transplantation. The aim of the current study was to investigate the effect of rabbit-ATG (r-ATG) combined with CsA as an intensive immunosuppressive therapy (IST) for acquired severe aplastic anemia (SAA) in children.
METHODS:
Dr. Warlick is an Assistant Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. Her clinical and research efforts focus on the treatment of hematologic malignancies. She has particular interest in myeloid malignancies and the development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases.